Table 1.
Clinicopathological characteristics of the study population with trastuzumab-based therapy.
| n (%) | |
|---|---|
| Age | |
| Median (range) | 63 (30–84) |
| Sex | |
| Male | 51 (73.9%) |
| Female | 18 (26.1%) |
| Specimen | |
| Biopsy | 18 (26.1%) |
| Surgical resection | 51 (73.9%) |
| Histology | |
| Intestinal | 49 (71.0%) |
| Diffuse | 15 (21.7%) |
| Mixed | 5 (7.2%) |
| Clinical stage (baseline) | |
| Early gastric cancer | 6 (8.7%) |
| Advanced gastric cancer | 63 (91.3%) |
| Metastasis (baseline) | |
| Absent | 34 (49.3%) |
| Present | 35 (50.7%) |
| HER2 IHC status | |
| 0 | 0 (0%) |
| 1+ | 2 (2.9%) a |
| 2+ | 19 (27.5%) |
| 3+ | 48 (69.6%) |
| Trastuzumab IHC status | |
| 0 | 32 (46.4%) |
| 1+ | 7 (10.1%) |
| 2+ | 5 (7.2%) |
| 3+ | 25 (36.2%) |
| PFS (months) | |
| Median (range) | 9.8 (0.1–147.4) |
| OS (months) | |
| Median (range) | 21.6 (0.1–147.4) |
| Total | 69 (100%) |
a These two cases had HER2 amplification confirmed by separate fluorescent in situ hybridization test. Abbreviation: IHC, immunohistochemistry; PFS, progression-free survival; OS, overall survival.